Depression in dermatological patients identified by the Mini International Neuropsychiatric Interview questionnaire

Cohen, Arnon D.; Ofek–Shlomai, Andr'e; Vardy, Daniel; Weiner, Zeev; Shvartzman, Pesach

doi:10.1016/j.jaad.2005.09.019

Cited by 34 publications

(23 citation statements)

References 22 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As an example, in an elderly population without cognitive impairment, the prevalence of current MDE estimated by use of the same MINI interview was 3.1% (1.8% of men and 4% of women) and lifetime MDE 21.6% (16.6% of men and 33.6% of women) [28]. In clinical samples, the prevalence of a current MDE assessed by the MINI was 9.6% for patients under a dermatologist's care [29] and 5.9% for primary care patients [30]. Accordingly, we found a prevalence of 14% for current dysthymia, whereas its prevalence is estimated to be 1.6% in the French general population and 2.1% in French women [31].…”

Section: Discussionmentioning

confidence: 99%

“…Les épisodes de MDE actuels étaient plus fréquents chez les patients hospitalisés que chez les autres (28 % vs 10 %, p = 0,02). Des troubles anxieux spécifiques étaient mis en évidence chez 37 [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] patients. Moins de 50 % des patients qui avaient des troubles de l'humeur avaient un traitement psychotrope.…”

Section: Medical Evaluationunclassified

See 1 more Smart Citation

Mood and anxiety disorders in systemic sclerosis patients

et al. 2011

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Medical Evaluationunclassified

Mood and anxiety disorders in systemic sclerosis patients

et al. 2011

View full text Add to dashboard Cite

“…The MINI is a standardized structured diagnostic interview that provides an extensive evaluation of patients psychiatric diagnoses meeting DSM-IV-TR criteria [APA, 2000] and ICD-10 criteria [WHO, 1992] and is widely used in clinical trials and for nonresearch purposes [Cohen et al, 2006;Fotiadou et al, 2006]. The MINI is a validated instrument for evaluation of emotional disorders in psychiatric populations [Brown et al, 2005;Cassano et al, 2004] and in general medical populations [Bunevicius et al, 2005;Friedman et al, 2005].…”

Section: Methodsmentioning

confidence: 99%

Screening for depression and anxiety disorders in primary care patients

Bunevicius¹,

Pečeliūnienė²,

Mickuvienė³

et al. 2007

Depress. Anxiety

View full text Add to dashboard Cite

Mood and anxiety disorders are highly prevalent in primary health care. In this study we assessed performance of the Hospital Anxiety and Depression Scale (HADS) for screening of depression and anxiety disorders in a population of primary care patients. A total of 503 primary care patients consecutively admitted to the primary care medical center in Kaunas, Lithuania, completed the study. We found that the HADS subscale of depression (HADS-D) at a cutoff score of 6 or more showed the best performance screening for a major depressive episode diagnosed by means of the Mini International Neuropsychiatric Interview (MINI), with a sensitivity of 80%, specificity of 69%, positive predictive value of 80%, negative predictive value of 92%, and area under the receiver operating characteristic (ROC) curve of 0.75. Performance of the HADS-D against MINI diagnosis of dysthymia was weak. The HADS subscale of anxiety (HADS-A) at a cutoff score of 9 or more showed the best performance screening for MINI diagnosis of overall anxiety disorders, with a sensitivity of 77%, specificity of 75%, positive predictive value of 53%, negative predictive value of 90%, and area under the ROC curve of 0.76. These results suggest that in primary care patients HADS is an adequate screening instrument for the MINI diagnoses of major depressive episode, but not for dysthymia at a cutoff score of 6, and for anxiety disorders at a cutoff score of 9.

show abstract

“…Even patients with mild psoriasis experience poor HRQoL 1-3 and the incidence of clinically significant psychiatric symptoms (including anxiety and depression) is much higher in patients with psoriasis (25%-43%) 4 compared with the general population (1.6%-10%). [5][6][7] One study of patients with psoriasis reported that they had more severe anxiety and depression compared with patients given the diagnosis of primary psychiatric disorders. 8 In addition, psoriasis has been associated with an increased risk of suicidal ideation.…”

mentioning

confidence: 99%